NCT06859931

Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial Evaluating the Efficacy and Safety of TQB3702 Tablets in Patients With Systemic Lupus Erythematosus

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

TQB3702 is a selective kinase inhibitor. This is a Phase II clinical study aimed at evaluating the efficacy and safety of TQB3702 tablets in patients with systemic lupus erythematosus.

Conditions

• Systemic Lupus Erythematosus

Interventions

Type	Name	Description
DRUG	TQB3702 Tablets	TQB3702 is a selective kinase inhibitor.
DRUG	TQB3702 Tablets+TQB3702 Placebo	TQB3702 is a selective kinase inhibitor； A placebo is a simulated drug whose physical properties, such as appearance, size, color, dosage form, weight, taste, and odor are substantially the same as the test drug, but cannot contain the active ingredients of the test drug.
DRUG	TQB3702 Placebo	TQB3702 Placebo without drug substance.

Timeline

• Start date: 2025-03-01
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2025-03-05
• Last updated: 2025-03-05

Locations

37 sites across 1 country: China